![Margaret M. Tarpey](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Margaret M. Tarpey
Corporate Officer/Principal bij University of Pittsburgh
Profiel
Margaret M.
Tarpey is the founder of Complexa, Inc. (founded in 2008).
She is currently a Professor at the University of Pittsburgh (since 2013).
Dr. Tarpey's education includes an undergraduate degree from the University of California, Riverside and a graduate degree from the University of California San Diego.
Actieve functies van Margaret M. Tarpey
Bedrijven | Functie | Begin |
---|---|---|
University of Pittsburgh | Corporate Officer/Principal | - |
Eerdere bekende functies van Margaret M. Tarpey
Bedrijven | Functie | Einde |
---|---|---|
Complexa, Inc.
![]() Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Oprichter | - |
Opleiding van Margaret M. Tarpey
University of California, Riverside | Undergraduate Degree |
University of California San Diego | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Complexa, Inc.
![]() Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Health Technology |